Onco Wiki / Regimen

Bortezomib + Lenalidomide + Dexamethasone (VRd), 4-6 induction cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-BORTEZOMIB DRUG-LENALIDOMIDE DRUG-DEXAMETHASONE
IDREG-VRD
TypeRegimen
Statusreviewed 2026-04-25 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-NCCN-MM-2025

Notes

Standard 1L induction regimen for transplant-eligible MM (4 cycles before harvest, then ASCT, then 2 cycles consolidation, then lenalidomide maintenance). For transplant-ineligible patients, VRd-lite (8-12 cycles, modified dosing per SWOG S0777) is the preferred 1L triplet. Standard-risk cytogenetics → VRd; high-risk → escalate to D-VRd (REG-DARA-VRD).

Used By

Contraindications

Handbook Chapters

Handbook Questions

Indication

Monitoring

Supportive Care